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Abstract
Background: A number of autoimmune diseases have been clinically and pathologically characterized. In
contrast, target antigens have been identified only in a few cases and, in these few cases, the knowledge of
the exact epitopic antigenic sequence is still lacking. Thus the major objective of current work in the
autoimmunity field is the identification of the epitopic sequences that are related to autoimmune reactions.
Our labs propose that autoantigen peptide epitopes able to evoke humoral (auto)immune response are
defined by the sequence similarity to the host proteome. The underlying scientific rationale is that antigen
peptides acquire immunoreactivity in the context of their proteomic similarity level. Sequences uniquely
owned by a protein will have high potential to evoke an immune reaction, whereas motifs with high
proteomic redundancy should be immunogenically silenced by the tolerance phenomenon. The
relationship between sequence redundancy and peptide immunoreactivity has been successfully validated
in a number of experimental models. Here the hypothesis has been applied to pemphigus diseases and the
corresponding desmoglein autoantigens.
Methods: Desmoglein 3 sequence similarity analysis to the human proteome followed by dot-blot/NMR
immunoassays were carried out to identify and validate possible epitopic sequences.
Results: Computational analysis led to identifying a linear immunodominant desmoglein-3 epitope highly
reactive with the sera from Pemphigus vulgaris as well as Pemphigus foliaceous. The epitopic peptide
corresponded to the amino acid REWVKFAKPCRE sequence, was located in the extreme N-terminal
region (residues 49 to 60), and had low redundancy to the human proteome. Sequence alignment showed
that human desmoglein 1 and 3 share the REW-KFAK–RE sequence as a common motif with 75% residue
identity.
Conclusion: This study 1) validates sequence redundancy to autoproteome as a main factor in shaping
desmoglein peptide immunogenicity; 2) offers a molecular mechanicistic basis in analyzing the commonality
of autoimmune responses exhibited by the two forms of pemphigus; 3) indicates possible peptide-
immunotherapeutical approaches for pemphigus diseases.
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Background
There are over 80 autoimmune diseases known or thought
to be autoimmune in nature and, as a group, autoimmune
diseases affect approximately 20% of the population.
Multiple mechanisms of autoimmunity induction have
been proposed including, among the others, molecular
mimicry [1], viral epitope delivery [2], generation of
neoantigenic epitopes after posttranslational modifica-
tion [3], unusual TCR-binding properties that permit
autoreactive T cells to escape deletion [4], presence of long
regions of extreme structural disorder in the autoantigens
[5], cellular injury and release of self antigens, which gen-
erate immune responses [1]. However, the mechanisms
leading to the breakdown of tolerance against enzyme
autoantigen molecules remain poorly understood. The
identification and comparative analysis of the autoanti-
genic immunoreactive determinants could elucidate the
molecular basis of the autoimmune disease and offer new
immunotherapeutical approaches.
Our labs have proposed that sequence similarity to the
host proteome may influence peptide immunogenicity
[6,7]. According to this hypothesis, only peptide motifs
having low similarity to the host proteome have the
potential to raise an immune response. Conversely, no
immune response can be evoked by antigenic protein
fragments that are repeatedly represented in the protein
set that form the proteome. In testing this work hypothe-
sis, our current research is focused to the proteomic defi-
nition of the epitopic peptide repertoire associated to
autoimmune diseases. In practice, based on the assump-
tion that peptide sequences that are scarcely represented
in human proteins might provoke autoimmune responses
by offering antigenic determinants unknown to (or, bet-
ter, scarcely encountered by) the immune system, we
search for epitopic sequences of human pathogenic
autoantigens by, first, selecting for autoantigen fragments
not shared with the human proteome and, then, analyz-
ing the immunoreactivity pattern of the not-shared pep-
tides using sera from patients hosting the autoimmune
disease. So far, the similarity hypothesis has been vali-
dated in a number of different experimental models [6-
13].
In this study, we used the pemphigus autoimmune skin
diseases and the corresponding desmoglein autoantigens
as an experimental model [14]. Indeed, pemphigus pro-
vides an exemplar paradigm for studying autoimmunity
because of its clear-cut antigenic characterization [14,15].
Desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1) are the
main autoantigenic target in Pemphigus vulgaris (PV) and
Pemphigus foliaceus (PF), respectively [16,17]. Moreover,
epitope mapping revealed that autoantibodies (AAbs)
from PV and PF patients recognize conformational
epitopes hosted in the amino terminal ectodomain of
Dsg3 and Dsg1 respectively [16,18]. However, although it
has been reported that pemphigus sera contain antibodies
against continuous epitopes [16,19], there is a general
lack of data on the definition and specificity of Dsg linear
epitopes. Therefore, given also that the molecular defini-
tion of linear Dsg autoepitopes could contribute to clarify
unresolved aspects of pemphigus autoimmunity [20-22],
we undertook an experimental study to define the linear
epitopic sequences in Dsg3 by using the criterion of non-
redundancy to human proteome as a search engine for
epitopic peptides.
Here we describe how the search for sequences uniquely
present in the human Dsg3 protein led to identifying an
amino terminal linear Dsg3 motif that immunoreacts
with sera from Pemphigus vulgaris as well as Pemphigus
foliaceous.
Materials and methods
Computer-assisted analyses
EC1/EC2 (aa 1–212) portion of human Dsg3 sequence
(SWISS-PROT, P32926) was analysed for redundancy to
human proteome using PIR protein database (141702
sequences) and peptide match program (pir.georget-
own.edu/pirwww) [23]. Sequence alignment was con-
ducted by using SIM – Local similarity program
(www.expasy.org) [24].
Sera
Sera were obtained from the outpatient Dermatology
Clinic at the Weill-Cornell Medical College, New York,
and Medical College of Wisconsin, Milwaukee. The diag-
nosis of PV and PF was made on the basis of clinical exam-
ination and biopsy as well as indirect IF serum titer. Sera
from prostate cancer patients were used as controls.
Peptides
Peptides were synthesized using standard Fmoc (N-(9-flu-
orenyl) methoxycarbonyl) solid phase peptide synthesis
(PeptidoGenic Research & Co., Livermore, CA.; Primm srl,
Milan, Italy). Peptide purity (>90%) was controlled by
analytical HPLC, and the molecular mass confirmed by
fast atomic bombardment mass spectrometry. Peptides
used for dotblot immunoassay are: Dsg149–
60REWIKFAAACRE, Dsg336–44EEMTMQQAK, Dsg349–
60REWVKFAKPCRE, Dsg3190–204LNSKIAFKIVSQEPA,
Dsg3373–380QVINVREG and Dsg3518–525NRYTGPYT. The
15N-labelled peptides used for NMR spectroscopy immu-
noanalysis are: Dsg349–60REWVKFAKPCRE, Dsg3373–
380QVINVREG and Dsg3518–525NRYTGPYT peptides (with
15N-labelled amino acid residues given underlined). Con-
trol recombinant proteins corresponding to the EC
domains of Dsg1 and Dsg3 [25] were generously provided
by Dr. M.S. Lin, Dept. of Dermatology, Medical College of
Wisconsin.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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Immuno-blot assays
Pemphigus serum reactivity against synthetic peptides was
tested by immunodotblot assays. Nitrocellulose mem-
brane (0.2 µm pore size, Biorad Laboratories, Milan, Italy)
was pretreated with 1% glutaraldehyde. Dsg3 protein (10
µg) or peptides (4 µg) were spotted on the activated mem-
branes and immunoassayed with PV or PF AAbs [8,11,13].
For Western blot assay, Dsg1 and Dsg3 proteins were
resolved on sodium dodecylsulfate-10% polyacrylamide
gel electrophoresis (SDS-10%PAGE), electroblotted onto
PVDF membrane (Biorad Laboratories, Milan), and
probed with PV or PF sera.
NMR spectroscopy
Spectroscopic analyses were carried out on sera pooled
and partially purified by precipitation with 40% saturated
(NH4)2SO4 (x 2). The precipitate was dissolved in phos-
phate-buffered saline (PBS), dialyzed against PBS with
several changes for 24 h at 4°C, then aliquoted and stored
at -20°C until assay. NMR spectra of the reaction of the
synthetic  15N-labelled Dsg349–60  REWVKFAKPCRE,
Dsg3373–380QVINVREG or Dsg3518–525NRYTGPYT peptide
(with 15N-labelled amino acid residues given underlined)
with partially purified AAbs from pooled sera of PV or PF
or prostate cancer patients as control were recorded at
298°K on a Bruker Avance DRX500WB spectrometer. The
spectra were acquired by heteronuclear single quantum
correlation (HSQC) experiments as already detailed
[8,11,26]. We used chemical shift statistics from the full
BioMagResBank database, where the calculated statistics
are derived from a total of 559392 chemical shifts
(www.bmrb.wisc.edu). Sequence-specific correction fac-
tor tabulations were applied to backbone 1H and 15N res-
onances [27]. Two-dimensional correlated spectroscopy
spectra of peptide-AAbs complex were obtained using
peptide:AAb ratio equal to 0.1:30, mg/mg. That is, NMR
samples contained either 0.1 mg free Dsg349–
60REWVKFAKPCRE (or Dsg3373–380QVINVREG or Dsg518–
525NRYTGPYT) peptide; or 30 mg PV AAbs complexed
with 0.1 mg Dsg349–60REWVKFAKPCRE (or Dsg3373–
380QVINVREG or Dsg3518–525NRYTGPYT) peptide; or 30
mg PF AAbs complexed with 0.1 mg Dsg349–
60REWVKFAKPCRE (or Dsg3373–380QVINVREG or
Dsg3518–525NRYTGPYT) peptide; or 30 mg control AAbs
complexed with 0.1 mg Dsg349–60REWVKFAKPCRE (or
Dsg3373–380QVINVREG or Dsg3518–525NRYTGPYT) pep-
tide, in 0.5 ml aqueous solution H2O/D2O (9:1, v/v).
Results
Searching EC1/EC2 Dsg 3 for sequences non-redundant to 
the human proteome
Since the Dsg antigenic portions recognized by AAbs from
PV patients mainly map to the NH2-terminal adhesive
domain9 [18,28], this preliminary study started by focus-
ing on the extracellular (EC) portion of human Dsg3. The
EC1/EC2 domain of Dsg3, spanning from amino acid 1 to
212, was searched for potential epitopic linear sequences
with low redundancy to the self-proteome using the PIR
protein database. Matching analysis to the human pro-
teome was performed using pentamer probes, being 5 to
6 amino acids the minimal immunoreactive peptide
length [29-31] Redundancy of a peptide sequence is
defined here by the number of identical pentamers in
common between the analyzed autoantigen and the
human proteome.
The Dsg3 sequence was dissected into 5-mer motifs that
were used as probes to scan the entire human proteome
databank. The Dsg3 pentamers were offset by one residue,
i.e. overlapped by four amino acids: MMGLF, MGLFP,
GLFPR, LFPRT, FPRTT, etc. The computational analysis
produced the histogram reported in Fig. 1. It can be seen
that the majority of EC Dsg3 pentamers have a number of
perfect match hits in the human proteome, by being
shared by a number of other human proteins. Only a few
peptide stretches are peculiarly owned by the EC1/EC2 of
PV Dsg3 antigen. According to the redundancy hypothesis
advanced by our labs [6-13], the non-redundant peptide
motifs, i.e. the sequences having a low number of matches
(or none at all) in common with the human proteome,
might be potentially immunogenic by offering possible
epitopic linear determinants unknown to (or rarely seen
by) the immune system. In this context, two peptides cor-
responding to Dsg336–44EEMTMQQAK and Dsg349–
60REWVKFAKPCRE sequences appeared of particular
interest, since these fragments present lowest similarity to
the human proteins and, additionally, host zero match
pentamers. Therefore, the corresponding peptides were
synthesized to be used in dot immunoassay with AAbs
from PV or PF patient sera. A peptide corresponding to
Dsg3190–204LNSKIAFKIVSQEPA sequence was also synthe-
sized since: i) susceptibility to PV is strongly linked to
DRB1*0402 serotype; ii) the Dsg3190–
Redundancy profile of the NH2 terminal portion of Dsg3 to  human proteome Figure 1
Redundancy profile of the NH2 terminal portion of Dsg3 to 
human proteome. The EC1/EC2 Dsg3 sequence aa1–212. 
was scanned for perfect matches to human protein 
sequences by using pentamers offset by one residue. Aster-
isk: value > 30.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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204LNSKIAFKIVSQEPA peptide has been reported to bind
DRB1*0402; iii) moreover, this peptide appears to be a
target for autoreactive T cells in PV patients with active dis-
ease [32]. In addition, two Dsg3 synthetic peptides,
Dsg3373–380QVINVREG and Dsg3518–525NRYTGPYT, were
used as controls having low redundancy to the human
proteome (8 and 12 total matches, respectively, in com-
mon with the human proteome), but no pentamers with
zero similarity to the human proteome. The similarity
profile scanning of the Dsg3 synthetic peptides used in
dot-immunoassay analyses with sera from PV and PF
patients is illustrated in Fig. 2.
Immunoreactivity of non-redundant EC1/EC2 Dsg3 
peptides
The synthetic peptides, selected as above described and
illustrated in Fig. 2, were bound to activated nitrocellulose
membrane and tested as potential antigenic epitopes
against serum from PV patients in dot immunoassays.
Because of reports of anti-Dsg immune responses in
healthy individuals [33-35], sera from prostate cancer
patients were used as controls. Sera from PF patients were
used as additional controls.
Fig. 3 shows that the non-redundant Dsg349–
60REWVKFAKPCRE peptide was immunoreactive with all
sera from PV. The Dsg3373–380QVINVREG sequence
showed some faint reactivity. The DRB1*0402 binding
and T cell epitope Dsg3190–204LNSKIAFKIVSQEPA peptide
[32] did not react with any of the human sera used in this
study. Interestingly Fig. 3 illustrates that the non-redun-
dant Dsg349–60REWVKFAKPCRE peptide was immunore-
active with AAbs from PF too.
NMR probing of Dsg349–60REWVKFAKPCRE peptide 
immunoreactivity
False positives as well as false negatives are a constant fea-
ture of immunoassays. Consequently, we controlled the
dot-blot results reported in Fig. 3 by NMR spectroscopy to
irrefutably demonstrate the immunoreactivity of Dsg349–
60REWVKFAKPCRE peptide with both PV and PF AAbs.
NMR spectroscopy measures the antigen-antibody bind-
ing reaction by monitoring nuclear chemical shifts, i.e. the
motional freedom of nuclei. However, application of
NMR technology to the analysis of the antigen-antibody
interaction is not unproblematic, since the high number
of amino acid residues complicates the assignment of spe-
cific chemical shift signals. Therefore, we enhanced the
NMR detection limit by measuring one-bond proton-
nitrogen shift correlations with two-dimensional (2-D)
phase-sensitive pulsed field gradient HSQC experiments
[26]. In addition, synthetic peptides containing 15N-
labelled amino acids were used in order to obtain greater
intensities and unequivocal resolution. Specifically, the
non-redundant Dsg349–60REWVKFAKPCRE, Dsg3373–
Redundancy scanning on the EC Dsg3 peptide sequences uti- lized in dot immunoassay analyses with human PV and PF  sera Figure 2
Redundancy scanning on the EC Dsg3 peptide sequences uti-
lized in dot immunoassay analyses with human PV and PF 
sera. Matching analysis to the human proteome was per-
formed using 5-mer peptide probes. Peptide: 1) Dsg336–
44EEMTMQQAK; 2) Dsg349–60 REWVKFAKPCRE; 3) 
Dsg3190–204LNSKIAFKIVSQEPA; 4) Dsg3373–380QVINVREG; 
5) Dsg3518–525NRYTGPYT.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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380QVINVREG, and Dsg3518–525NRYTGPYT peptides
(with 15N-labelled amino acid residues given underlined)
were synthesized and chemical shift changes following
AAb addition were monitored in two-dimensional corre-
lated spectroscopy spectra as reported in Fig. 4, 5, and 6,
respectively. Each spot in the figures is an NMR signal rep-
resenting the 1H-15N one-bond coupling of the labelled
amino acid residues in the peptide.
Table 1 lists the numerical values of the theoretical and
experimental chemical shifts of the 15N-labelled amino
acid residues in the Dsg349–60REWVKFAKPCRE peptide.
Theoretical values were calculated by using chemical shift
statistics from BioMagResBank (www.bmrb.wisc.edu)
plus sequence-dependent factors to correct deviations due
to local sequence effects [27]. Experimental values derive
from the resonance spectrum of the reactions illustrated
in Fig. 4, and indicate the chemical shift of the labelled
amino acid residues in the free peptides in solution vs.
those obtained following AAb addition to the peptide
solution.
Specifically, Fig. 4 shows the reaction between human
AAbs and the immunoreactive Dsg349–
60REWVKFAKPCRE peptide. Fig. 4A reports the Arg, Val,
Phe, and Ala selective 1H-15N correlations of the free pep-
tide in aqueous solution, with the upper part of Fig. 4A
displaying the Arg cross-peak signals due to the H and N
atoms of amino η residues. On the whole, Fig. 4A clearly?
shows that all of the expected signals are present and in
basic agreement with the theoretical data relative to the
15N-labelled amino acids (see chemical shift values in
Table 1). The addition of AAbs from control cancer sera
did not alter the REWVKFAKPCRE resonance signals, so
that the spectrum of Fig. 4B could be assigned by reference
to the control spectrum of the free peptide reported in Fig.
4A, both qualitatively and quantitatively. On the contrary,
a complete signal deletion was provoked by the addition
of AAbs from PF sera as illustrated in Fig.4C, upper and
lower parts. Practically, Fig. 4C demonstrates that the PF
AAbs were able to specifically neutralize and quantita-
tively precipitate the low similarity Dsg349–
60REWVKFAKPCRE peptide. In the presence of PV AAbs,
well resolved resonances for 15N-labelled epitopic
REWVKFAKPCRE peptide residues were detectable (Fig.
4D, upper and lower panels), but the signal intensity was
much weaker when compared to the control spectra
reported in Fig. 4, panels A and B. That indicates that only
Immunoreactivity of PV, PF or prostate cancer human sera towards EC Dsg3 peptides Figure 3
Immunoreactivity of PV, PF or prostate cancer human sera towards EC Dsg3 peptides. Sera: A) control sera from prostate 
cancer patients; B) Pemphigus foliaceous sera; C) Pemphigus vulgaris sera. Immunoreactivity of each serum was assayed by dot-
blot as described under Methods. Indirect IF titer is reported for each PF and PV serum. Antigens: Dsg3, recombinant EC Dsg 
3 protein; peptides with low redundancy to the human proteins: Dsg336–44EEMTMQQAK and Dsg349–60 REWVKFAKPCRE; 
peptide with high affinity to DRB*0402: Dsg3190–204LNSKIAFKIVSQEPA; control peptides: Dsg3373–380QVINVREG and Dsg3518–
525NRYTGPYT.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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a part of the 15N-labelled peptide had been complexed
and buried by PV AAbs. No precipitation reaction was
observed by using the control 15N-labelled Dsg3373–
380QVINVREG and Dsg3518–525NRYTGPYT peptides (not
shown).
Dsg1 and Dsg3 cross-react with PF and PV sera: sharing of 
the 75% consensus motif REW-KFAK–RE
It is res iudicata in pemphigus pathologies that Dsg3 is the
autoantigen of the vulgaris form, whereas Dsg1 is the
autoantigen of the foliaceous form [14,15,17-19,33]. In
agreement with this statement, in the experiments illus-
trated in Figs. 3 and 4, PF AAbs were initially used as addi-
tional controls. On the other hand, the peculiar data
emerging from Figs. 3 and 4 is the highly specific reaction
between the PF AAbs preparation and the peptide from
PV-associated Dsg3 autoantigen. Indeed, given the caveat
that the extent of the 15N-labelled peptide reaction moni-
tored in the NMR spectroscopy analyses depends on the
AAb titer of each of the pooled sera, the NMR spectra
reported in Fig. 4 indicated that the reaction extent with
AAbs from PF sera was even higher than that monitored
with AAbs from PV sera. The finding was of interest also
in the light of reports indicating a common desmoglein
background in PV and PF, and coexistence of the two
pemphigus forms in the same patient [36,37].
To better understand and define the cross-reactivity
between the PF AAbs and the PV associated Dsg3 peptide,
we analyzed Dsg1 and Dsg3 protein immunoreactivity
towards AAbs from PV and PF by Western blot analysis.
Fig. 5, panels A and B, show that: i) both PV and PF AAbs
recognize a linear desmoglein determinant; ii) the linear
desmoglein determinant is common to Dsg1 and Dsg3, so
confirming the NMR spectroscopic immunoreaction
reported in Fig. 4C.
The cross reaction between the PF AAbs and the PV asso-
ciated Dsg3 peptide was further investigated by Dsg1/
Dsg3 sequence alignment. The sequence analysis demon-
strates 75% identity in the fragment spanning aa 49 to 60:
with REW-KFAK–RE as a common consensus motif, and
suggests that the shared amino acids of the consensus
motif may represent the epitopic residues recognized by
Dsg R E W I K F A A A C R E
Dsg R E W V K F A K P C R E
1
3
=
=
||| :||| |||
1H-15N NMR HSQC spectra and relative 1-D contour plots of the low- redundancy Dsg349–60REWVKFAKPCRE peptide 15N- labelled at residues 1, 4, 6, 7 and 11 Figure 4
1H-15N NMR HSQC spectra and relative 1-D contour plots of the low- redundancy Dsg349–60REWVKFAKPCRE peptide 15N-
labelled at residues 1, 4, 6, 7 and 11. A) free peptide in solution; plus AAbs from B) prostate cancer, C) PF, or D) PV patients. 
Upper panels: portions of the HSQC spectra showing resonances from residues 1, 4, 6, 7 and 11. Lower panels: expanded 
region of the HSQC spectra showing resonances from the residues 4, 6, 7 and 11, by being 1-Arg at terminal position. 15N-
labelled residues are given underlined.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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both PV and PF sera, so providing a theoretical molecular
framework to the data reported in Figs. 3, 4 and 5. Final
experimental confirmation was obtained in immunodot-
blot assays by using the synthetic Dsg149–
60REWIKFAAACRE peptide with PV and PF sera. Fig. 5,
panel C, illustrates that PF AAbs recognize both Dsg149–
60REWIKFAAACRE and Dsg349–60 REWVKFAKPCRE pep-
tides. Likewise, also PV AAbs recognize Dsg149–
60REWIKFAAACRE as well as Dsg349–60REWVKFAKPCRE
peptide (Fig. 5, panel D).
Discussion
Using computational biology and proteomics, and apply-
ing sequence uniqueness as a search criterium, we have
characterized a linear low-redundant Dsg3 segment which
is immunorecognized by sera from PV patients as well as
PF patients. These data appear of scientific, clinical, and
therapeutical interest.
Scientifically, the present study demonstrates that analyt-
ical dissection of the human proteome allows to compar-
atively analyze the molecular basis of complex multi-
faceted diseases such as the pemphigus, and precisely
identify autoantigen portions involved in immune
responses. As a matter of fact, the methodology used in
this study was extremely effective for individuating one
new desmoglein epitope. Sets of 40 synthetic peptides,
each 15 residues in length and overlapping by ten amino
acid residues, should had been screened to scan the EC1/
EC2 Dsg3 sequence by using canonical peptide-mapping
analysis. In our approach identification of an immunodo-
minant linear desmoglein epitope involved only 6 syn-
thetic peptides. The application of the proteomic
approach to find unique sequences led to rapid, effective
and inexpensive epitope identification when compared to
other methods,
Clinically, we note that although other investigators have
analyzed desmogleins for patterns of continuous immu-
noreactive peptides [19,38,39], this is the first time, as far
as we know, that a linear determinant on Dsg3 is identi-
fied as a precise amino acid sequence immunoreactive
with patients' sera. Likewise, this is the first time that a
Cross-reactivity of human recombinant EC Dsg1 or EC Dsg3  proteins with PF and PV sera Figure 5
Cross-reactivity of human recombinant EC Dsg1 or EC Dsg3 
proteins with PF and PV sera. Panels A and B: Western 
blot analysis of PF or PV serum immunoreactivity towards 
human recombinant EC Dsg1 or EC Dsg3 protein. Control: 
phosphorylase was used as a control protein. Panels C and 
D: Dot blot analysis of PF or PV serum immunoreactivity 
towards peptide: 1) Dsg3190–204LNSKIAFKIVSQEPA, 2) 
Dsg349–60 REWVKFAKPCRE, and 3) Dsg149–
60REWIKFAAACRE.
Table 1: Chemical shifts of 15N-labelled residues in Dsg49-60REWVKFAKPCRE peptide, and changes on control, PV or PF Aab addition
15N-residue1 Chemical Shift Values:
Theoretical2: Experimental3:
Free peptide Free peptide Control Aabs +PV Aabs +PF Aabs
1HN1 5 N 1HN1 5 N 1HN1 5 N 1HN1 5 N 1HN1 5 N
1-Arg4 6.78   77.6 6.95   80.6 7.02   80.7 7.24   81.2 - -
4-Val 8.65 120.8 8.18 122.7 8.18 122.5 8.16 122.5 - -
6-Phe 8.42 121.7 7.97 119.3 7.97 119.0 7.96 119.0 - -
7-Ala 8.29 122.3 8.40 120.0 8.40 120.0 8.38 119.8 - -
11-Arg4 6.78   77.6 7.22   81.4 7.27   81.6 7.20   81.6 - -
8.14 119.6 8.14 117.9 8.13 117.7 8.12 117.9 - -
115N-amino acid position in the peptide. 2 Theoretical chemical shift values were derived from bmrb.wisc.edu, and corrected for deviations due to 
local sequence effects [27]. 3 Experimental values from resonance spectra reported in Fig. 4. 4 Average value of chemical shifts relative to the H and 
N atoms of η amino residues in arginine. The chemical shifts relative to the H and N atoms of α amino residue are undetectable in 1-Arg because 
of the NH2 terminal position.Journal of Translational Medicine 2006, 4:37 http://www.translational-medicine.com/content/4/1/37
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common link between PV and PF is presented in terms of
a common Dsg3/Dsg1 immunoreactive motif, i.e. the
consensus REW-KFAK–RE sequence. Given the caveat that
immunogenicity and pathogenicity are not synonymous
and further studies are necessary in order to assess the
(patho)physiological significance of the present data,
undoubtedly these experimental results might be of help
in defining the autoantibody response of pemphigus dis-
eases. Indeed, pemphigus is a group of diseases of the skin
and mucous membranes that 1) include different forms
and variants, 2) are characterized by complex autoanti-
body profiles, and 3) present blistering process as a mini-
mum common clinical denominator [40-42].
Consequently, a major goal in understanding pemphigus
autoimmunity is the identification of critical epitopes
along the antigen portions involved in the calcium-
dependent cell-cell adhesion process. In this context, the
data presented in this work, describing the NH2 terminal
calcium-adhesive Dsg349–60REWVKFAKPCRE immunore-
active peptide, might represent a prelude to an exact defi-
nition of the entire Dsg linear epitope pattern. Indeed, the
individuation of the consensus motif as a common
sequence recognized by PF and PV sera is an experimental
point that might help in the fine definition of the AAb
profile in pemphigo diseases. Moreover, it has to be men-
tioned that also the monoclonal humoral response to the
ectodomain of human Dsg3 targets within the Dsg349–60
REWVKFAKPCRE sequence [13]. This is an additional rea-
son for further studying Dsg349–60 sequence in the context
of the induction of bullous skin disease resembling PV
through passive transfer of PV AAbs [43].
Therapeutically, the usage of proteomic sequence unique-
ness as a guiding principle in identifying epitopic
sequences along autoantigenic proteins offers the possi-
bility of effective peptide-immunotherapies in autoim-
mune diseases. The peptide-immunotherapy approach is
currently being explored with encouraging results in many
autoimmune diseases [44-46]. Indeed, short peptide frag-
ments might be used to selectively block and neutralize
autoantibodies, once the effective epitopic sequences
have been determined and the definition between immu-
nogenic and pathogenic epitopes is clearly drawn. Moreo-
ver, the precise identification of amino acid sequences
uniquely present in the autoantigen of interest would also
eliminate the side effects deriving from possible cross-
reactions. In this context, the proteomics-defined REWVK-
FAKPCRE sequence represents a suitable candidate for a
possible peptide-immunotherapy in pemphigus diseases.
Abbreviations
Dsg, desmoglein; EC, extracellular; PV, Pemphigus vulgaris;
PF,  Pemphigus foliaceous; HSQC, heteronuclear single
quantum correlation; AAbs, autoantibodies.
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